S S Engel

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Samuel S Engel
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Cardiovasc Diabetol 12:3. 2013
  2. pmc Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ USA
    BMC Endocr Disord 10:7. 2010
  3. pmc Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
    S S Engel
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Int J Clin Pract 64:984-90. 2010

Collaborators

  • Barry J Goldstein
  • Debora Williams-Herman
  • Gregory T Golm
  • Michael J Davies
  • Keith D Kaufman
  • Hua Guo
  • Bret J Musser
  • Jeremy Johnson
  • Elizabeth Round

Detail Information

Publications3

  1. pmc Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Samuel S Engel
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Cardiovasc Diabetol 12:3. 2013
    ..To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators...
  2. pmc Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams-Herman
    Merck Research Laboratories, Rahway, NJ USA
    BMC Endocr Disord 10:7. 2010
    ..The purpose of the present analysis is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies...
  3. pmc Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
    S S Engel
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Int J Clin Pract 64:984-90. 2010
    ..0.10 events per 100 patient-years, respectively). Preclinical and clinical trial data with sitagliptin to date do not indicate an increased risk of pancreatitis in patients with T2DM treated with sitagliptin...